Profilo
Stephen F.
Betz is the founder of Crinetics Pharmaceuticals, Inc., founded in 2008, where the title held is Chief Scientific Officer since 2021.
Former jobs include Director-Endocrinology & Metabolism at Neurocrine Biosciences, Inc. from 2003 to 2009, and Head-Laboratory Efforts at GeneFormatics, Inc. from 2001 to 2003.
Education history includes an undergraduate degree from the University of Delaware conferred in 1987 and a doctorate from The University of North Carolina at Chapel Hill conferred in 1993.
Precedenti posizioni note di Stephen Betz
| Società | Posizione | Fine |
|---|---|---|
| CRINETICS PHARMACEUTICALS | Fondatore | 01/09/2026 |
| NEUROCRINE BIOSCIENCES, INC. | Corporate Officer/Principal | 01/05/2009 |
GeneFormatics, Inc.
GeneFormatics, Inc. BiotechnologyHealth Technology Provides protein function determination | Corporate Officer/Principal | 01/01/2003 |
Formazione di Stephen Betz
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
GeneFormatics, Inc.
GeneFormatics, Inc. BiotechnologyHealth Technology Provides protein function determination | Health Technology |
University of Delaware
University of Delaware Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets therapeutics for endocrine-related diseases | Health Technology |
















